NeuroDex research library
Parkinson’s disease and Lewy body dementia: blood biomarker library
Alpha-synuclein is the defining pathology of Parkinson’s disease, Lewy body dementia and multiple system atrophy. Seed amplification assays confirm it in CSF; measuring it in blood, at every visit, is what trials still need. These articles cover diagnosis, enrollment, stratification and target engagement.
Start here
Understanding Parkinson’s Disease: Symptoms, Causes, and TreatmentParkinson’s disease is a progressive neurodegenerative disorder that mainly affects movement. An overview of its symptoms, causes and treatment.Alpha-Synuclein Biomarkers for Parkinson’s DiseaseExplore Alpha-Synuclein biomarkers’ impact on diagnosing Parkinson’s disease with insights from NeuroDex.Lewy Body Dementia (LBD)Approximately 1.3 million individuals in the U.S. are affected by Lewy Body Dementia, a condition with unknown causes involving genetic factorsMultiple System AtrophyExplore biomarkers for neurological disorders and insights on Multiple System Atrophy in this informative article.
Blood biomarkers for trials
Misdiagnosed at Enrollment: Parkinson’s Look-Alikes in Early-Stage TrialsEarly Parkinson’s trials enroll on a clinical diagnosis that is often wrong. How blood biomarkers, including neuron-derived EV α-synuclein, improve…Parkinson’s Starts a Decade Before Diagnosis. Can Blood Find It?An alpha-synuclein blood test can detect Parkinson’s pathology years before diagnosis. What the data show in prodromal cohorts, and where CSF still…Beyond Alpha-Synuclein: Measuring Neuronal Function to Stratify Parkinson’s PatientsAlpha-synuclein biomarkers show who has Parkinson’s, not why. How neuron-derived EVs measure neuronal function to stratify patients by disease…How to Select Blood Biomarkers for a Parkinson’s TrialBlood biomarkers selection for a Parkinson’s trial depends on the decision the marker must support.Lewy Body Dementia: Building a Blood Biomarker Strategy Without Serial CSFClinical criteria miss 40% of LBD cases and co-pathology is the rule. How to build a blood biomarker panel for Lewy body dementia trials without…Alpha-Synuclein Works. It’s Not Trial-Ready Yet.Plasma alpha-synuclein assays are nearing CSF-level accuracy, but raw plasma still falls short of a trial endpoint. Here is the gap and how to close…Alpha-Synuclein Target Engagement: What CSF and Imaging Can’t Show YouCSF and Imaging Miss Alpha-Synuclein Target Engagement. CSF and DAT imaging diagnose Parkinson’s disease but miss real-time target engagement.Alpha-Synuclein Seed Amplification Assays: The Game-Changer for Early PD Detection and Clinical Trial StratificationDiscover how Alpha-Synuclein Seed Amplification Assays aid in early Parkinson’s disease detection and understanding alpha-synuclein’s role.
NeuroDex research
Blood biomarker for alpha-synuclein pathology, validated at autopsyA 1,304-person NeuroDex and Columbia study found alpha-synuclein in neuron-derived extracellular vesicles tracks Lewy body pathology confirmed at…NeuroDex Powers New Neuron EV RNA-Seq Dataset in AMP PDRDExplore the new Neuron EV RNA-Seq dataset in AMP PDRD, advancing research and insights for scientists and researchers.Michael J. Fox Foundation Funds Research on a Potential Parkinson’s BiomarkerParkinson’s disease is a progressive neurological disorder affecting millions worldwide.The MJFF study aims to discover biomarkerNeuroDex, Inc., Announces Award from The Michael J. Fox FoundationNeuroDex Announces Award from MJFF. Blood Test for Parkinson’s Stratification based on Extracellular Vesicles.NeuroDex Announces Second Award from The Michael J. Fox FoundationNeuroDex Announces Second Award from The Michael J. Fox Foundation to study “Neuronal extracellular vesicles blood-based biomarker
Clinical trial landscape
Parkinson’s Disease Clinical Trials in 2026:Explore advancements in Parkinson’s Disease clinical trials and biomarkers for neurological disorders in 2026.Latest Advances in Parkinson’s Clinical TrialsDiscover the latest breakthroughs and insights in research that drive Parkinson’s clinical trials forward for better patient outcomes.Pioneering Biotech Efforts in the Battle Against Parkinson’s DiseaseSeveral biotech and pharmaceutical companies are actively involved in the battle against Parkinson’s disease.

